超声造影用于局灶性肝病灶:准确度如何
本文综述六氟化硫微泡(美国商品名Lumason,其他地区商品名Sonovue)超声造影表征局灶性肝病灶的文献,为美国研究者提供该技术准确度的背景;该药近期获FDA批准用于儿童和成人局灶性肝病灶表征,欧洲和亚洲已使用多年并有大量敏感度和特异度文献,另有少数研究直接比较超声造影与增强CT和增强MRI。
要点
- 六氟化硫微泡是美国唯一获FDA批准用于局灶性肝病灶表征的超声造影剂。
- 该药在欧洲和亚洲已使用多年,已有大量关于其敏感度和特异度的文献。
- 少数研究直接比较了超声造影与增强CT和增强MRI对局灶性肝病灶的表征。
核心结论
- 本文综述文献为美国研究者提供超声造影表征局灶性肝病灶准确度的背景,重点为六氟化硫微泡(美国商品名Lumason,其他地区商品名Sonovue)。
研究设计与样本
- 综述;检索并汇总六氟化硫微泡超声造影表征局灶性肝病灶的文献,并纳入少数直接比较超声造影与增强CT和增强MRI的研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
With the recent FDA approval for characterization of focal liver lesions (FLL) in both pediatric and adult patients using Lumason (sulfur hexafluoride microbubbles), increased use of ultrasound contrast for routine clinical use is expected. This agent has been available for many years in Europe and Asia, and a large body of literature is available regarding the sensitivity and specificity of this agent. In addition, a few studies have directly compared CEUS to CECT and CEMRI for the characterization of focal liver lesions. This paper reviews the literature to provide a background to investigators in the United States as to the accuracy of CEUS in the characterization of FLL. This paper reviews the literature regarding sulfur hexafluoride microbubbles (Lumason in the USA and Sonovue in the rest of the world) since it is the only FDA approved agent in the USA for characterization of FLL. The results of other ultrasound contrast agents which are not FDA approved for abdominal indications (approval for cardiac indications) most likely will have similar results.
引用
- Barr RG. Contrast enhanced ultrasound for focal liver lesions: how accurate is it? Abdom Radiol (NY). 2018. PMID: 28718042. doi:10.1007/s00261-017-1257-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。